Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Weight loss in patients with type 2 diabetes can improve glycemic control, lower blood pressure, and improve dyslipidemia. Glucagon-like peptide (GLP-1) receptor agonists are associated with weight loss and have potentially beneficial effects on cardiovascular risk biomarkers; however, there is limited information to indicate whether these effects remain outside of clinical trials. RESEARCH DESIGN AND METHODS: Medical records from the General Electric Centricity research database were analyzed retrospectively to evaluate the relationship between weight loss and glycemic control and changes in blood pressure and lipids in patients with type 2 diabetes initiating therapy with exenatide, sitagliptin, or insulin. Baseline and follow-up (90–365 days after the index date) for weight, A1C, fasting blood glucose (FBG), blood pressure, triglycerides, and LDL, HDL, and total cholesterol were assessed. RESULTS: A total of 6,280, 5,861, and 32,398 patients receiving exenatide, sitagliptin, or insulin, respectively, were included in the analysis. Exenatide-treated patients lost a mean ± SD of 3.0 ± 7.33 kg, sitagliptin-treated patients lost 1.1 ± 5.39 kg, and insulin-treated patients gained 0.6 ± 9.49 kg. There was a significant association between weight loss and a reduction in A1C and FBG with exenatide only and a reduction in blood pressure for all therapies. Weight loss was associated with some improvements in lipids, primarily in the GLP-1 receptor agonist group, with little association in the insulin group. CONCLUSIONS: Weight reduction with GLP-1 receptor agonists was associated with a shift toward a more favorable cardiovascular risk profile. Outcome trials are needed to determine whether improvement in biomarkers translates into a reduction in cardiovascular events in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, weight reduction can markedly improve blood sugar control and decrease the risk of cardiovascular disease [40].”
From The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [11]
In the citing paper
“Weight loss is associated with an improved prognosis for overweight T2D patients and obese individuals.”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [11]
In the citing paper
“Weight loss was significantly associated with small reductions in both SBP and DBP in all treatment groups.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [208]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“At high concentrations they also slow gastric emptying and reduce food intake (16).”
BackgroundReduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522 · cited 1×
“improves lipid levels (9), and even a mod-”
BackgroundBeneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 2×
“Data from clinical trials with exenatide, a GLP-1 receptor agonist, suggest that it has potentially beneficial effects on biomarkers of cardiovascular risk in patients with type 2 diabetes, including lowering blood pressure and improving dyslipidemia (19).”
BackgroundMethodIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Intentional weight loss and mortality among overweight individuals with diabetes.
Williamson, D. F., Thompson, T. J., Thun, M., Flanders, D., Pamuk, E., & Byers, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.10.1499 · Cited by 558
Research works printed but not linked: 1
- Bergenstal, 2009, Exenatide once weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment, Diabetes, 58, A165
Cited by
Items 101–156 of 156
Humalog (lispro) for type 2 diabetes
Esposito, K., Capuano, A., & Giugliano, D. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.728584 · Cited by 12
Patient Factors Associated with Glucagonlike Peptide 1 Receptor Agonist use with and without Insulin
Hirsch, I. B., Xu, Y., Davis, K. L., & Calingaert, B. (2011) · Endocrine Practice · doi:10.4158/ep11014.or · Cited by 9
Self-citationPawaskar, M. D., Bonafede, M., Johnson, B. H., Fowler, R., Lenhart, G. M., & Hoogwerf, B. J. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-20 · Cited by 11
Wang, N., Zhang, J., Xing, X., Yang, Z., Zhang, B., Wang, X., & Yang, W. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12486 · Cited by 9
Afonso, M., Ryan, F., Pitcher, A., & Lew, E. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1304395 · Cited by 10
Wang, B., Ni, Y., ZHONG, J., & Sun, F. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00167.x · Cited by 11
Incretin-Related Drug Therapy in Heart Failure
Vest, A. R. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0232-6 · Cited by 10
Cardiovascular Effects of Incretin Therapy in Diabetes Care
Kim, J., & Samson, S. L. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0035 · Cited by 11
Soltani, S., Yazdanpanah, Z., Razmpoosh, E., Vasmehjani, A. A., Rostampour, K., Lotfi, M., Kaviani, M., Forbes, S. C., Baker, J. S., & Salehi‐Abargouei, A. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf065 · Cited by 14
Addo, S. A., Nti, C., Vuvor, F., Adjimani, J. P., & Steiner‐Asiedu, M. (2019) · Journal of Nutrition and Metabolism · doi:10.1155/2019/4729040 · Cited by 9
Lindberg, N. M., Vega‐López, S., LeBlanc, E. S., Leo, M. C., Stevens, V. J., Gille, S., Arias‐Gastélum, M., & Meenan, R. T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.489882 · Cited by 9
Shaw, J. E., Gallwitz, B., Han, J., Hardy, E., & Schernthaner, G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13022 · Cited by 8
Neyestani, T. R., Salekzamani, S., Kalayi, A., Majd, H. A., Houshiarrad, A., Nikooyeh, B., & Shariátzadeh, N. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0075 · Cited by 7
Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus
Wang, S., Dong, W.-B., Dong, X., Wen-min, Z., Wang, F.-F., Han, F., & Yan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.20282 · Cited by 7
The “Weight” of Obesity on Arterial Hypertension
Noce, A., & Daniele, N. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.87774 · Cited by 8
Korytkowski, M. T., Brooks, M. M., Lombardero, M., DeAlmeida, D. R., Kanter, J. E., Magaji, V., Orchard, T. J., & Siminerio, L. M. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814564183 · Cited by 7
Acute Cholesterol-Lowering Effect of Exendin-4 in Ldlr−/− and C57BL/6J Mice
Hori, M., Hasegawa, Y., Hayashi, Y., Nakagami, T., & Harada‐Shiba, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60921 · Cited by 8
Korytkowski, M. T., Karslioglu French, E., Brooks, M., DeAlmeida, D., Kanter, J., Lombardero, M., Magaji, V., Orchard, T., & Siminerio, L. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000206 · Cited by 6
Chen, J., Chang, C., Kuo, M., Tung, S., Tsao, C., & Tsai, C.-J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.009 · Cited by 6
Wu, L., Zhou, N., Sun, J.-Y., Yu, H., & Wang, R. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001270 · Cited by 6
Advances in Drug Treatments for Companion Animal Obesity
Zomer, H. D., & Cooke, P. S. (2024) · Biology · doi:10.3390/biology13050335 · Cited by 10
Faghri, P. D. (2014) · International Journal of Physical Medicine & Rehabilitation · doi:10.4172/2329-9096.1000255 · Cited by 5
A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes
Cornell, S. A. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12040 · Cited by 6
The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes
Gillani, S. M. R., & Singh, B. M. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.022 · Cited by 5
The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes
Hollander, P. A. (2013) · US Endocrinology · doi:10.17925/use.2013.09.02.101 · Cited by 6
Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Johnson, K., & Schurr, K. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6227 · Cited by 5
Pujante, P., Gil, M. D. H., Román, L. M., Gómez, M. F., Zafra, M. V. G., & Massó, J. T. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.10.025 · Cited by 4
Patel, M. B., Elmore, L. K., Edgerton, L., & Whalin, L. M. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110567 · Cited by 4
Curtis, L. R., Holt, H., Richardson, T., Knott, J., & Partridge, H. (2016) · Practical Diabetes · doi:10.1002/pdi.1991 · Cited by 5
Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
Asti, A., D’Alessandro, A., Zito, F. P., Nardi, S., Sarnelli, G., Maresca, G., & D'alessandro, G. (2016) · Italian Journal of Medicine · doi:10.4081/itjm.2016.558 · Cited by 5
Cystic fibrosis-related diabetes: links, challenges, and future directions
Kelly, A. T., & Sheikh, S. (2015) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s68278 · Cited by 6
Intensification of medical management in type 2 diabetes: A real-world look at primary care practice
Zekarias, K., Davey, C. S., & Seaquist, E. R. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107477 · Cited by 4
Myat, A., Redwood, S. R., Arri, S. S., Gersh, B. J., Bhatt, D. L., & Marber, M. S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00635-6 · Cited by 5
Lipid Lowering Effect of Anti Diabetic Agents-Recent Research
Pavithra, N., & Chaitanya, M. (2015) · International journal of pharma research and review · Cited by 6
Understanding the Molecular Crosstalk in Biological Processes
El-Esawi, M. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77821 · Cited by 1
Fujitani, Y. (2012) · Juntendō Igaku/Juntendo igaku · doi:10.14789/pjmj.58.490 · Cited by 1
Xu, M., Zhang, P., Lv, W., Chen, Y., Chen, M., Leng, Y., Hu, T., Wang, K., Zhao, Y., Shen, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127003 · Cited by 1
Bizoń, A., Borkowska, J., Franik, G., & Piwowar, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157097 · Cited by 2
Lahouti, M., Arzhang, P., & Azadbakht, L. (2025) · Phytotherapy Research · doi:10.1002/ptr.70074 · Cited by 2
Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Nogueira, K. C. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2012.tde-27072012-155318
Diabetes Mellitus: Dipeptidyl Peptidase 4 Inhibitors and Cardiovascular Outcomes
Pastromas, S. (2014) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v9i2.601
Armando Pérez, M., Aure, G., & Ruíz-Contreras, J. (2012) · Revista Venezolana de Endocrinología y Metabolismo · Cited by 7
Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis
Cho, E.-H. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.138
Sitagliptyna — nowoczesny lek w terapii cukrzycy typu 2
Kujawska-Łuczak, M., & Pupek‐Musialik, D. (2011) · Forum Zaburzeń Metabolicznych
Secular and Longitudinal Trends in Body Weight in a Large Population of Veterans, 2000-2014
Tamas, M. J. (2016) · Digital Archive @ GSU · doi:10.57709/7945584
Jawaharlal, R., & Maske, P. G. R. (2017) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2017/861
The Effect of Exenatide Therapy in Previously Insulin-Treated Type 2 Diabetic Patients
Yasar, H., Ceyhan, B. O., Pamuk, B. O., Demirpence, M., Ertugrul, O., & Ertugrul, D. (2017) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2017.447
Insulin, Body Mass, and Growth in Young Cystic Fibrosis Patients
Hameed, S., & Verge, C. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800051-9.00024-9 · Cited by 1
Zhou, R., Duncan, K., Lopez, J., Rich, K., & Swislocki, A. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0122
Taher, J. (2017) · TSpace (University of Toronto) · Cited by 1
Dietary resistant starch improved maternal glycemic control in Goto-Kakizaki rat
Shen, L. (2010) · Louisiana State University · doi:10.31390/gradschool_dissertations.1476 · Cited by 2
Myat, A., Redwood, S. R., Arri, S. S., Gersh, B. J., Bhatt, D. L., & Marber, M. S. (2021) · Figshare · doi:10.6084/m9.figshare.13979203
Sarkar, R., Wu, P. K. W., Binang, H. B., Rajan, P. K., Hosen, S. Z., Xu, Z., Pirola, R. C., Wilson, J. S., Apte, M. V., & Perera, C. J. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2026.159736 · Cited by 1
Dépôts de graisse ectopique : étude de leur développement et de leur modulation
Abdesselam, I. (2016) · theses.fr (ABES) · doi:10.70675/1f016024z175cz4b35z8034za3b418cfe9c3 · Cited by 1
Sarkar, R., Perera, C. J., Hossain, M. J., Tyma, V. M., Perera, D., Khan, T., Binang, H., Rajan, P., Mekapogu, A. R., Hosen, S. M. Z., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.10.015
Metadata
- Authors
- Horton, E. S., Silberman, C., Davis, K. L., & Berria, R.
- Affiliations
- Joslin Diabetes Center (US)
- Roche Laboratories, Nutley, New Jersey; and
- RTI Health Solutions (US)
- Corresponding author
- Horton, Edward S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-05-11
- Volume
- 33
- Issue
- 8
- Pages
- 1759-1765
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2909058
- OpenAlex
- W2099903872
- Cited by
- 156
- References
- 23
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 2 · 2017: 14 · 2016: 9 · 2015: 13 · 2014: 16 · 2013: 15 · 2012: 21
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, weight loss, glycemic control, GLP-1 receptor agonists, exenatide, sitagliptin, insulin therapy, cardiovascular risk markers, blood pressure, dyslipidemia, HbA1c, fasting blood glucose, lipid profile
- MeSH terms
- Sitagliptin Phosphate, Exenatide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Pyrazines, Triazoles, Venoms, Cohort Studies, Weight Loss, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.